RESET-5 and RESET-6 for Cancer: A Critical Evidence Review of Ivermectin, Mebendazole and Repurposed Drug Combinations
Abstract
Background: Drug repurposing has attracted increasing interest in oncology because several inexpensive, already-approved medicines have demonstrated anticancer effects in laboratory models. A series of articles published in 2026 proposed increasingly complex combinations termed RESET-5 and RESET-6, centered on ivermectin, mebendazole, metformin, sulforaphane, aged garlic extract and, in later versions, agents such as niclosamide or celecoxib.
Objective: To critically synthesize the biological rationale and available human evidence surrounding these proposed combinations, while distinguishing hypothesis-generating observations from demonstrated clinical efficacy.
Methods: The source articles were reviewed alongside current PubMed-indexed literature, clinical-trial records and relevant methodological literature. Evidence was categorized as mechanistic, in vitro, animal, observational, early clinical or randomized clinical evidence.
Results: Ivermectin, mebendazole and niclosamide have demonstrated biologically interesting anticancer effects in multiple experimental systems, including effects on Wnt/β-catenin, PI3K/AKT/mTOR, STAT3, microtubules, apoptosis and cancer stem-cell phenotypes. However, these findings do not establish that the drugs produce clinically meaningful tumor regression or survival benefits when combined in RESET-5 or RESET-6. A 2026 systematic review of mebendazole in brain tumors found substantial preclinical activity but concluded that clinical efficacy remained modest, inconsistent and inconclusive. A 2025 review of ivermectin similarly concluded that large randomized trials demonstrating anticancer benefit are lacking.
Conclusion: RESET-5 and RESET-6 are best regarded as hypothesis-generating drug-repurposing frameworks, not validated pan-cancer treatments or cancer-prevention protocols. Their most scientifically defensible role at present is as a framework for generating testable clinical hypotheses and designing appropriately controlled trials.
Keywords: RESET-5 cancer, RESET-6 cancer protocol, ivermectin cancer, mebendazole cancer, niclosamide cancer, cancer stem cells, repurposed cancer drugs, metabolic oncology, ivermectin mebendazole combination
1. Introduction
Cancer treatment has increasingly moved from a one-drug/one-target paradigm toward combinations that simultaneously address tumor proliferation, metabolism, immune escape, treatment resistance and the tumor microenvironment.
This has created interest in drug repurposing: testing established medicines for new indications. The attraction is straightforward. Existing drugs may already have known pharmacology, manufacturing infrastructure and substantial human safety experience for their approved indications.
But repurposing creates an important scientific trap: biological plausibility is not equivalent to clinical efficacy.
Diverse cancer hallmarks targeted by repurposed non-oncology drugs. Source: Nature 2024
A drug may inhibit a cancer-associated pathway in a cell culture experiment yet fail clinically because the required concentration cannot be achieved safely in humans, because the tumor adapts through another pathway, or because the biology observed in one cancer subtype does not translate to another.
This distinction is particularly important for ivermectin, mebendazole and niclosamide.
2. What Are RESET-5 and RESET-6?
The 2026 source articles (11,12,13) describe a progression from simpler metabolic combinations toward increasingly broad multi-pathway approaches.
RESET-5
The proposed RESET-5 concept combines:
- Ivermectin
- Mebendazole
- Metformin
- Sulforaphane
- Aged garlic extract
The conceptual objective is to attack several biological characteristics of cancer simultaneously, including cellular metabolism, microtubule function, inflammatory signaling, oxidative stress, epigenetic regulation and cancer stem-cell biology.
RESET-6 and related variants
Later proposals add another experimental component, most notably niclosamide or celecoxib.
The source material describes variants including RESET-6C, RESET-6N and RESET-7CN, depending on whether celecoxib, niclosamide or both are added.
The theoretical rationale is understandable: if resistant tumors can bypass one inhibited pathway, simultaneous blockade of several pathways might reduce the available escape routes.
The critical problem is that this remains a therapeutic hypothesis. Demonstrating pathway coverage on paper does not demonstrate that the combination produces superior outcomes in patients.
3. The Cancer Stem-Cell Hypothesis
A central concept underlying RESET-5/6 is the cancer stem-cell (CSC) model.
CSC-like populations have been proposed to contribute to tumor initiation, heterogeneity, treatment resistance and relapse. Several developmental signaling pathways are implicated in maintaining stem-like phenotypes, including:
- Wnt/β-catenin
- Notch
- Hedgehog
- STAT3
- PI3K/AKT/mTOR
- NF-κB
- TGF-β
These pathways are biologically important, but the phrase "block all cancer stem cells" should be avoided. Cancer is not a single disease, CSC phenotypes are heterogeneous, and pathway activity varies substantially among tumor types and individual tumors.
Furthermore, pathway inhibition does not automatically translate into tumor eradication. Tumors can activate alternative signaling networks, alter metabolism, change cellular state and interact with the surrounding microenvironment.
4. Ivermectin: What Does the Evidence Actually Show?
Ivermectin is an established antiparasitic medicine that has attracted substantial interest as a potential repurposed oncology drug.
Laboratory studies have reported effects involving apoptosis, cellular proliferation, oxidative stress and signaling pathways including Wnt/β-catenin and PI3K/AKT/mTOR. Experimental work has also investigated effects on drug-efflux mechanisms and cancer stem-like populations.
However, the critical translational question is whether these effects occur at concentrations that are both clinically achievable and safe in humans.
A 2025 review concluded that the anticancer evidence for ivermectin remains dominated by preclinical studies and that there are no large randomized controlled trials establishing therapeutic benefit in cancer.
5. Mebendazole: A More Developed Repurposing Candidate
Mebendazole is another established antiparasitic drug with a substantial experimental oncology literature.
Its proposed anticancer mechanisms include disruption of microtubule dynamics, effects on signaling kinases, anti-angiogenic activity, apoptosis and interference with pathways involved in tumor growth and stem-cell biology.
Brain tumors have attracted particular interest because experimental work suggests that mebendazole can reach the central nervous system and because glioma models have demonstrated several potentially relevant mechanisms.
However, the distinction between preclinical promise and demonstrated patient benefit remains critical.
A 2026 systematic review covering 22 studies—17 preclinical and five clinical/population studies—found broad experimental activity but concluded that clinical efficacy in brain tumors remained modest, inconsistent and inconclusive. The authors called for better comparative trials and improved pharmacokinetic and formulation studies.
6. The METRICS Experience: Important but Frequently Overstated
The original COC-style metabolic combination provides an important case study in why evidence grading matters.
The METRICS study investigated a combination of:
- Metformin
- Atorvastatin
- Doxycycline
- Mebendazole
The study was designed as an open-label, non-randomized, single-arm real-world investigation rather than a conventional randomized controlled trial.
The published methodology paper reported preliminary retrospective glioblastoma observations that generated considerable interest. However, the publication subsequently received an Expression of Concern from the journal.
Consequently, statements such as "the METRICS trial proved that the four-drug protocol increases survival by almost one year" are too strong for a rigorous medical article.
A more accurate formulation is:
The METRICS program generated hypothesis-generating observational evidence suggesting that a four-drug metabolic combination might warrant further investigation in glioblastoma, but it did not provide randomized evidence establishing causality or clinical efficacy.
7. Sulforaphane and Aged Garlic Extract
RESET-5 also incorporates nutraceutical components intended to broaden biological coverage.
Sulforaphane, an isothiocyanate derived from cruciferous vegetables, has been investigated for effects involving Nrf2 signaling, epigenetic regulation, oxidative stress, apoptosis and several cancer-associated pathways.
Aged garlic extract contains multiple bioactive compounds that have been investigated for antioxidant, inflammatory and vascular effects.
These observations are scientifically interesting, but nutritional and phytochemical research presents another translational challenge: formulation, absorption, metabolism, tissue concentration and dose-response relationships vary considerably.
Therefore, laboratory activity should not be translated directly into statements that a particular supplement "kills cancer stem cells" in patients.
8. Niclosamide: The Most Interesting Experimental CSC Component?
Niclosamide is particularly interesting because experimental studies have identified activity against several pathways relevant to cancer stem-cell biology.
Laboratory research has reported inhibition of Wnt/β-catenin, mTOR and STAT3 signaling, including activity against experimental chemoresistant ovarian cancer models and CSC-enriched populations.
Other laboratory work has reported that niclosamide can interfere with Wnt/β-catenin signaling and enhance radiosensitivity in experimental triple-negative breast cancer models.
These findings support further research but do not establish niclosamide as a clinically effective pan-cancer CSC treatment.
The bioavailability problem
One of the major challenges with niclosamide repurposing is pharmacokinetics. Standard oral niclosamide has limited systemic exposure, creating a potentially important disconnect between concentrations that inhibit pathways experimentally and concentrations achievable safely in humans.
This is precisely why formulation research matters. A formulation that changes absorption or systemic exposure is effectively a different pharmacological problem and requires its own safety and efficacy evaluation.
9. Celecoxib and the Tumor Microenvironment
Celecoxib is a selective COX-2 inhibitor. COX-2/PGE2 signaling is biologically relevant to inflammation, angiogenesis, immune regulation and tumor microenvironment biology.
There is therefore a plausible rationale for investigating COX-2 inhibition in selected cancers or cancer-associated inflammatory states.
But celecoxib is not a benign universal anticancer drug. COX-2 inhibition has recognized cardiovascular, renal and gastrointestinal considerations, and its risk-benefit ratio depends on the patient and clinical context.
Small clinical studies have investigated celecoxib in cancer-related conditions and premalignant disease, demonstrating that the drug can be studied clinically, but these studies should not be interpreted as proof that adding celecoxib to RESET-5 improves cancer survival.
10. RESET-5 as Cancer Prevention: A Critical Correction
One of the source articles explicitly explored whether RESET-5 could theoretically prevent cancer.
This is an important question but requires an especially high evidentiary threshold.
Cancer prevention is not the same as cancer treatment.
A drug combination administered to healthy people must have an exceptionally favorable benefit-risk ratio because the individual is not currently suffering from cancer. Even a small risk of serious toxicity can outweigh an uncertain theoretical reduction in future cancer risk.
The available evidence does not demonstrate that RESET-5 prevents cancer in healthy humans.
Accordingly, RESET-5 should not be promoted as a preventive medication regimen.
For cancer prevention, the strongest evidence remains concentrated around established interventions such as tobacco avoidance, appropriate screening, maintaining a healthy body weight, physical activity, reducing alcohol exposure and addressing recognized environmental or occupational carcinogens.
11. Why a "Pan-Cancer" Protocol Is Scientifically Difficult
The claim that one six-drug combination could be effective against nearly every cancer is attractive but scientifically ambitious.
There are more than 200 recognized cancer types and numerous molecular subtypes within them. Two tumors arising in the same organ may have radically different genomic, metabolic and immunological characteristics.
Examples include:
- EGFR-mutated versus KRAS-mutated lung cancer
- HER2-positive versus triple-negative breast cancer
- MSI-high versus microsatellite-stable colorectal cancer
- Hormone-sensitive versus castration-resistant prostate cancer
- IDH-mutant versus IDH-wild-type gliomas
- Different molecular subtypes of leukemia and lymphoma
A pathway that is essential in one tumor may be redundant in another.
Consequently, the strongest version of the RESET hypothesis is not:
"RESET-6 treats virtually all cancers."
A scientifically defensible version is:
"Multi-pathway repurposed-drug combinations provide a testable hypothesis for targeting metabolic adaptation, treatment resistance and selected cancer stem-cell-associated signaling pathways across multiple tumor types."
12. Evidence Hierarchy
The following hierarchy should be applied when interpreting RESET-5/6 claims:
Level 1 — Molecular mechanism
A compound interacts with a biological target or pathway.
Level 2 — Cell culture
Cancer cells respond to the compound under laboratory conditions.
Level 3 — Animal models
Tumor growth or survival changes in experimental animals.
Level 4 — Case reports
Individual patients experience an outcome temporally associated with treatment.
Level 5 — Observational cohorts
Outcomes are measured in groups of patients but without randomized treatment assignment.
Level 6 — Prospective controlled studies
Treatment is systematically evaluated against a comparator.
Level 7 — Randomized controlled trials
Patients are randomly assigned, reducing major sources of confounding.
Level 8 — Replicated randomized evidence
Multiple independent trials consistently demonstrate clinically meaningful benefit.
Most RESET-5/6 evidence currently resides in Levels 1–3, with selected components reaching Levels 4–5. That is very different from having Level 7–8 evidence for the complete combination.
13. Why Combination "Synergy" Cannot Be Assumed
One of the most important problems with multi-drug protocols is the assumption that combining several theoretically active agents automatically creates synergy.
True pharmacological synergy must be demonstrated experimentally.
For a six-agent combination, researchers would ideally need to determine:
- Whether the combination produces greater-than-additive activity
- Which components are actually responsible for the effect
- Whether one drug alters the pharmacokinetics of another
- Whether toxicity increases disproportionately
- Whether the combination interferes with standard treatment
- Whether immune checkpoint therapy is affected
- Whether tumor response differs by molecular subtype
- Whether resistance eventually develops
A pathway diagram showing six drugs hitting multiple targets is therefore a hypothesis map, not evidence of therapeutic synergy.
14. The Ivermectin + Mebendazole Combination
The ivermectin/mebendazole combination is particularly appealing because the two agents have different experimental mechanisms.
Ivermectin has been investigated for effects on signaling, apoptosis and drug-efflux mechanisms, while mebendazole has established experimental effects on microtubules and several additional cancer-associated pathways.
However, the combination itself requires direct clinical testing.
It is not scientifically valid to add together the individual evidence for ivermectin and the individual evidence for mebendazole and then conclude that the combination has proven efficacy.
This is a fundamental principle of combination-drug research:
15. A 2026 Evidence Audit
Ivermectin
- Mechanistic rationale: Strong
- Preclinical evidence: Substantial
- Human observational evidence: Emerging
- Randomized oncology evidence: Insufficient
- Clinical conclusion: Investigational
Mebendazole
- Mechanistic rationale: Strong
- Preclinical evidence: Substantial
- Early human experience: Available
- Demonstrated clinical efficacy: Inconclusive
- Clinical conclusion: Investigational
Niclosamide
- Mechanistic rationale: Strong for selected pathways
- Preclinical evidence: Substantial
- Human oncology evidence: Limited
- Pharmacokinetic challenge: Important
- Clinical conclusion: Investigational
Celecoxib
- Biological rationale: Plausible in selected settings
- Human clinical experience: Extensive for its approved indications
- Pan-cancer efficacy: Not established
- Clinical conclusion: Context-dependent; not a validated RESET component
Metformin
- Mechanistic rationale: Strong metabolic rationale
- Epidemiological evidence: Extensive but heterogeneous
- Randomized oncology evidence: Mixed and cancer-specific
- Clinical conclusion: Not established as a universal anticancer drug
Sulforaphane and aged garlic extract
- Mechanistic evidence: Interesting
- Preclinical evidence: Moderate to substantial depending on endpoint
- Clinical anticancer evidence: Limited
- Clinical conclusion: Nutritional/experimental adjuncts, not proven cancer treatments
16. The Most Important New Evidence: A 2026 Observational Study
A 2026 prospective observational cohort reported outcomes among 197 cancer patients prescribed ivermectin plus mebendazole through a U.S. telemedicine platform. Of the participants, 122 completed six-month follow-up. The study reported high adherence and substantial rates of self-reported clinical benefit.
This is potentially important because it represents a larger human dataset than isolated case reports.
However, the study has major limitations that prevent it from establishing efficacy:
- It was observational rather than randomized.
- The outcomes were substantially based on patient-reported information.
- Only 61.9% completed the six-month follow-up.
- Participants also received conventional treatments, supplements and dietary interventions.
- There was no randomized untreated or standard-of-care comparator.
- Confounding and selection bias cannot be excluded.
- The study has subsequently received an Expression of Concern.
Therefore, its findings should be considered hypothesis-generating rather than proof of efficacy.
17. What a Proper RESET Clinical Trial Should Look Like
If the RESET hypothesis is to move from online discussion into mainstream scientific medicine, the next step should not be increasingly elaborate dosing schedules.
The next step should be controlled clinical experimentation.
A reasonable development pathway would include:
- Preclinical combination testing to determine whether the proposed agents actually demonstrate synergy.
- Pharmacokinetic studies to determine whether biologically relevant concentrations can be safely achieved.
- Drug-interaction studies involving standard cancer therapies.
- Biomarker selection to identify tumors most likely to respond.
- Phase I studies to establish safety.
- Phase II studies to evaluate preliminary efficacy.
- Randomized Phase III trials where promising signals are confirmed.
Clinical trials should also record objective outcomes such as:
- Overall survival
- Progression-free survival
- Objective response rate
- Duration of response
- Minimal residual disease where applicable
- Quality of life
- Treatment-related adverse events
- Pharmacokinetic exposure
- Molecular biomarkers
The National Cancer Institute clinical-trial search provides a current resource for identifying legitimate oncology trials.
18. What RESET-5/6 Gets Right
Despite the exaggerated claims surrounding some versions of these protocols, several underlying scientific questions are legitimate.
- Cancer is an adaptive biological system.
- Drug resistance is a major cause of treatment failure.
- Metabolism can influence tumor behavior.
- Wnt, STAT3, PI3K/AKT/mTOR and other pathways are important in selected cancers.
- Cancer stem-like populations deserve continued investigation.
- Drug repurposing can generate useful oncology hypotheses.
- Combination therapy can be more effective than single-agent therapy when biologically justified.
- Affordable medicines deserve rigorous investigation when there is a credible mechanistic rationale.
19. Safety Is Part of the Evidence Question
The fact that a medicine has been used safely for one approved indication does not automatically establish that it is safe:
- at different doses;
- for prolonged periods;
- in patients with advanced cancer;
- in combination with several other drugs;
- during chemotherapy;
- during immunotherapy;
- in patients with impaired liver or kidney function.
Drug-drug interactions and organ-specific toxicities therefore need to be evaluated individually.
Patients with cancer should disclose every prescription drug, over-the-counter medicine, supplement and experimental therapy to their oncology team.
20. Final Evidence-Based Assessment
RESET-5 and RESET-6 represent an interesting example of the growing interest in multi-target drug repurposing for oncology.
The biological rationale is not frivolous. Ivermectin, mebendazole and niclosamide have genuine experimental anticancer literature, and multiple pathways highlighted by the RESET framework are well established areas of cancer biology.
But the central scientific problem remains translational.
Most of the evidence supporting the complete RESET combinations is mechanistic, preclinical, observational or anecdotal—not randomized clinical evidence.
The distinction matters enormously.
A laboratory experiment can demonstrate that a drug affects Wnt signaling. A mouse study can demonstrate tumor growth inhibition. A case report can document an unexpected remission. An observational cohort can generate a promising association.
None of these, individually or collectively, establishes that a six-drug combination improves survival compared with modern standard treatment.
The most defensible conclusion in 2026 is therefore:
RESET-5 and RESET-6 should currently be classified as experimental, hypothesis-generating multi-drug repurposing strategies. Their underlying mechanisms warrant further investigation, but there is insufficient high-quality clinical evidence to recommend them as established treatments or preventive regimens for cancer.
22. Research Priorities
The most valuable next-generation research would move beyond increasingly complicated theoretical protocols and answer five practical questions:
- Which cancers are biologically most susceptible?
- Which biomarkers predict response?
- Can effective tumor concentrations be safely achieved?
- Do combinations actually outperform their individual components?
- Do they improve objective clinical outcomes when added to standard care?
If those questions are answered positively in well-controlled studies, the repurposing hypothesis could become clinically meaningful.
Until then, the RESET framework belongs in the category of experimental translational oncology—not established cancer medicine.
References and Further Reading
- Agrawal S, et al. A New Method for Ethical and Efficient Evidence Generation for Off-Label Medication Use in Oncology. Frontiers in Pharmacology. 2019. METRICS methodology. Full article.
- Frontiers Editorial Office. Expression of Concern: A new method for ethical and efficient evidence generation for off-label medication use in oncology. 2023. Expression of Concern.
- 2026 systematic review of mebendazole repurposing for brain tumors. British Journal of Clinical Pharmacology.
- 2025 review of ivermectin in cancer treatment. Current Oncology Reports.
- Antitumor effects of ivermectin at clinically feasible concentrations. PubMed.
- Niclosamide inhibition of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. PubMed.
- Niclosamide and Wnt/β-catenin signaling in triple-negative breast cancer. PubMed.
- ClinicalTrials.gov. METRICS — NCT02201381.
- NCI. Find Cancer Clinical Trials.
- 2026 prospective observational study of ivermectin plus mebendazole in cancer patients. PubMed. Note: expression of concern applies.
- https://justusrhope.substack.com/p/the-strongest-csc-blocker-meets-the
- https://justusrhope.substack.com/p/can-the-reset-5-prevent-cancer
- https://justusrhope.substack.com/p/a-new-ivermectinmebendazole-cocktail
- https://catsinhats.substack.com/p/reset-6-dr-justusa-rhope-oraz-adresy
- Cancer Advisor. 30 Best Alternative Cancer Treatments 2026: Proven Interventions
Frequently Asked Questions
Is RESET-5 a proven cancer treatment?
No. RESET-5 is a proposed experimental combination. Its biological rationale is based substantially on preclinical and observational evidence, not randomized clinical trials demonstrating improved cancer survival.
Is RESET-6 proven to work against all cancers?
No. There is currently no clinical evidence demonstrating that RESET-6 is an effective treatment across all cancer types. Different cancers have substantially different molecular and biological characteristics.
Does ivermectin kill cancer stem cells?
Ivermectin has demonstrated effects on cancer cells and stem-like populations in experimental models. That does not establish that it eliminates cancer stem cells in human patients at clinically safe exposures.
Does mebendazole treat cancer?
Mebendazole is a legitimate experimental repurposing candidate. Laboratory and early clinical research is encouraging enough to justify further study, but current clinical evidence does not establish meaningful anticancer efficacy.
Can RESET-5 prevent cancer?
There is currently no clinical evidence demonstrating that RESET-5 prevents cancer in healthy people. It should therefore not be used as a cancer-prevention medication regimen outside a properly designed clinical study.
Is niclosamide a cancer stem-cell blocker?
Niclosamide inhibits several pathways associated with cancer stem-cell biology in laboratory studies, including Wnt/β-catenin, STAT3 and mTOR. Whether this translates into clinically meaningful benefit remains unproven.
Can repurposed drugs be combined with standard cancer treatment?
Sometimes, but this should be decided individually by the treating oncology team. "Natural," "repurposed" or "already approved" does not mean a combination is automatically safe with chemotherapy, radiation, targeted therapy or immunotherapy.
What is the strongest evidence for these protocols?
The strongest evidence currently concerns the individual biological mechanisms and preclinical activity of certain components. Evidence for the complete RESET-5/RESET-6 combinations is substantially weaker.
What would prove RESET-6 works?
A properly designed clinical development program would require pharmacokinetic and safety studies followed by controlled trials measuring objective tumor response, progression-free survival, overall survival, quality of life and adverse events.
Editorial Disclosure
This article is an independent evidence review and does not endorse self-medication or experimental cancer treatment. It has been deliberately revised to distinguish hypothesis, mechanism, preclinical evidence, observational evidence and clinical proof. Claims originating from the reviewed Substack articles are treated as hypotheses unless independently supported by higher-quality evidence.
Last medically reviewed/updated: August 12, 2026
.png)
.png)
Comments
Post a Comment